Zobrazeno 11 - 20
of 29
pro vyhledávání: '"Anne Calleja"'
Autor:
Steven Le Gouill, Anne‐Marie Ngo Nloga, Cecile Bally, Thierry Guillaume, Thomas Cluzeau, Anne Calleja, Patrice Chevallier, Pierre Fenaux, Eurydice Angeli, Maxime Jullien, Alice Garnier, Pierre Peterlin, Lionel Ades, Amandine Le Bourgeois
Publikováno v:
British Journal of Haematology. 190:461-464
Autor:
Sophie de Guibert, Lauren Veronese, Loic Ysebaert, Charles Herbaux, Olivier Tournilhac, Emmanuelle Tchernonog, Anne-Sophie Michallet, Florence Cymbalista, Damien Roos-Weil, Bruno Pereira, Jehan Dupuis, Pierre Feugier, Anne Calleja, Florian Bouclet, Caroline Dartigeas, Sandy Amorim, Anaise Blouet, Marie-Sarah Dilhuydy, Florence Nguyen-Khac, Pierre Morel, Nataliya Dmytruck, Kamel Laribi, Alain Delmer, Thérèse Aurran, Bénédicte Hivert, Romain Guieze
Publikováno v:
Annals of Hematology
Annals of Hematology, Springer Verlag, 2021, 100 (4), pp.987-993. ⟨10.1007/s00277-021-04419-w⟩
Annals of Hematology, Springer Verlag, 2021, 100 (4), pp.987-993. ⟨10.1007/s00277-021-04419-w⟩
The BCL2 inhibitor venetoclax is transforming the management of patients with chronic lymphocytic leukemia (CLL), given its high efficacy in relapsed/refractory CLL as observed in both early-phase and randomized clinical trials. The present study aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bcfa17e3bf9239371765d63d44c9ea8
https://hal.uca.fr/hal-03441025
https://hal.uca.fr/hal-03441025
Publikováno v:
Revue du Rhumatisme. 87:307-309
Autor:
Anne, Calleja, Florian, Bouclet
Publikováno v:
Bulletin du cancer. 108(1)
Autor:
Anne Calleja
Publikováno v:
Hématologie. 27:45-46
Autor:
Seongseok Yun, Bérangère Dadone-Montaudie, David A. Sallman, Rami S. Komrokji, Anne Calleja, Jean Michel Karsenti, Lauris Gastaud, Chimène Moreilhon, Najla Al Ali, Thomas Cluzeau, Lionel Mannone, Guillaume Robert, Patrick Auberger, Sophie Raynaud
Publikováno v:
European journal of haematologyREFERENCES. 104(5)
Introduction Therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML) are defined as complications of previous cytotoxic therapy. Azacitidine (AZA), a hypomethylating agent, has showed activity in t-MDS/AML. Objectives We evalu
Autor:
Anne Calleja, Antoine Benichou
Publikováno v:
Hématologie. 23:397-405
Autor:
Florian Bouclet, Anne Calleja
Publikováno v:
Bulletin du Cancer. 108:12-13
Autor:
Anne Calleja
Publikováno v:
Hématologie. 26:181-182
Publikováno v:
Joint Bone Spine. 86:661-662